Company Percheron Therapeutics Limited Börse Stuttgart
Equities
AWY0
AU0000317281
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0479 EUR | -0.83% | -1.63% | +40.41% |
06-17 | Percheron Therapeutics Appoints CFO | MT |
06-03 | Percheron Therapeutics Names Chief Medical Advisor | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
ATL 1102
80.4
%
| 2 | 98.1 % | 2 | 80.4 % | -11.14% |
Unallocated
19.6
%
| 0 | 1.9 % | 0 | 19.6 % | +1,026.23% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +8.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Garner
CEO | Chief Executive Officer | - | 23-05-07 |
Anthony Filippis
COO | Chief Operating Officer | - | 22-10-31 |
Andrew McKenzie
PRN | Corporate Officer/Principal | - | - |
Alicia Mellors
SEC | Corporate Secretary | - | 21-02-23 |
George Tachas
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Price
BRD | Director/Board Member | 68 | 21-10-03 |
James Garner
CEO | Chief Executive Officer | - | 23-05-07 |
Chairman | - | 21-03-21 |
Company contact information
Percheron Therapeutics Ltd.
Collins Place 35 Collins Street
3000, Melbourne
+61 3 9827 8999
http://www.PercheronTx.comSector
Sales per Business
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.31% | 122B | |
+21.36% | 116B | |
+22.18% | 27.03B | |
-21.28% | 20.36B | |
-16.89% | 16.43B | |
-17.99% | 15.91B | |
-44.74% | 15.6B | |
+61.18% | 14.94B | |
+3.36% | 13.59B |
- Stock Market
- Equities
- PER Stock
- AWY0 Stock
- Company Percheron Therapeutics Limited